Do Janus kinase inhibitors represent a therapeutic option
for severe COVID-19?
Baricitinib, fedratinib, and ruxolitinib are potent and selective
JAK-STAT signaling inhibitors approved for indications such as
rheumatoid arthritis and myelofibrosis. These drugs are powerful
anti-inflammatory medications that may reduce the systemic levels of
cytokines associated with COVID-19.192 Indeed, in a
pilot study of 12 COVID-19 patients, baricitinib limited the CSS and was
beneficial for the patients.193